Literature DB >> 8599872

The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine.

L Hogarth1, M English, L Price, R Wyllie, A D Pearson, A G Hall.   

Abstract

Glutathione(GSH) has been implicated as an important factor in the detoxification of many electrophilic xenobiotics, including agents used in cytotoxic chemotherapy. Maintenance of high levels of GSH in normal tissues is believed to be important in the prevention of drug-induced toxicity. Previous studies have indicated that exposure of cells to some toxic electrophiles both in vitro and in vivo can cause a temporary decrease in intracellular levels of GSH. In this paper we report that in a series of 22 children and young adults treated with high dose melphalan (ten courses studied, all 200 mg/m2), cisplatin (eight courses, 80-104 mg/m2) or carboplatin (seven courses, 507-750 mg/m2) there was no significant alteration in the level of plasma, erythrocyte or urine GSH in the period immediately following drug administration. Fluctuations in the level of GSH in mononuclear cells were observed in some patients but did not follow any consistent pattern and were similar to those observed in a series of nine normal adult controls over the same time course. These results suggest that for melphalan, cisplatin and carboplatin, drug-GSH adduct formation is insufficient to cause a measurable decrease in intracellular GSH levels in normal peripheral haematopoietic cells during the course of treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599872     DOI: 10.1007/s002800050415

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  36 in total

1.  Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.

Authors:  M J Tilby; C Johnson; R J Knox; J Cordell; J J Roberts; C J Dean
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

2.  Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan.

Authors:  D W Hedley; T J McElwain; J L Millar; M Y Gordon
Journal:  Lancet       Date:  1978-11-04       Impact factor: 79.321

3.  Assay of biological thiols by a combination of high-performance liquid chromatography and postcolumn reaction with 6,6'-dithiodinicotinic acid.

Authors:  J Nishiyama; T Kuninori
Journal:  Anal Biochem       Date:  1984-04       Impact factor: 3.365

4.  Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels.

Authors:  H H Bailey; J J Gipp; M Ripple; G Wilding; R T Mulcahy
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

5.  gamma-Glutamyl transpeptidase (gamma-GT) and maintenance of thiol pools in tumor cells resistant to alkylating agents.

Authors:  S Ahmad; L Okine; R Wood; J Aljian; D T Vistica
Journal:  J Cell Physiol       Date:  1987-05       Impact factor: 6.384

6.  Elevation of glutathione in phenylalanine mustard-resistant murine L1210 leukemia cells.

Authors:  S Ahmad; L Okine; B Le; P Najarian; D T Vistica
Journal:  J Biol Chem       Date:  1987-11-05       Impact factor: 5.157

7.  Determination of erythrocyte superoxide dismutase, catalase, glucose-6-phosphate dehydrogenase, reduced glutathione and malonyldialdehyde in uremia.

Authors:  D P Chauhan; P H Gupta; M R Nampoothiri; P C Singhal; K S Chugh; C R Nair
Journal:  Clin Chim Acta       Date:  1982-08-04       Impact factor: 3.786

8.  Determination of reduced, oxidized, and protein-bound glutathione in human plasma with precolumn derivatization with monobromobimane and liquid chromatography.

Authors:  A M Svardal; M A Mansoor; P M Ueland
Journal:  Anal Biochem       Date:  1990-02-01       Impact factor: 3.365

9.  Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma.

Authors:  R Corbett; R Pinkerton; J Pritchard; S Meller; I Lewis; J Kingston; T McElwain
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

10.  Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan.

Authors:  J L Millar; B N Hudspith; N M Blackett
Journal:  Br J Cancer       Date:  1975-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.